<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>The Wolfson Inst for Biomedical Research</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A5EEF8B8-F133-43A5-8E49-CA03803B21B5"><gtr:id>A5EEF8B8-F133-43A5-8E49-CA03803B21B5</gtr:id><gtr:firstName>Frances</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Gotch</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/365B37B6-7E8D-4B2E-A39D-02E92F44F91E"><gtr:id>365B37B6-7E8D-4B2E-A39D-02E92F44F91E</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Boshoff</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9825083"><gtr:id>75FF3B61-C073-4CCD-BF0E-B749CE01575C</gtr:id><gtr:title>KSHV infection and immunity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9825083</gtr:grantReference><gtr:abstractText>Kaposi sarcoma herpesvirus (KSHV) causes certain cancers. In particular, KSHV causes Kaposi sarcoma and lymphomas. Kaposi sarcoma is a tumour found particularly in immunosuppressed individuals. That means this cancer is common in HIV infected individuals and also in those immunosuppressed after organ transplant. Kaposi sarcoma and KSHV provide an ideal opportunity to study the role of the immune system in controlling cancer. We will study how the immune system fights this virus and how KSHV escapes recognition by the immune system. By understanding the immune system?s role in controlling these cancers we can develop new treatments not only for Kaposi?s sarcoma but also for other cancers. Such therapies include vaccines to treat or prevent the development of cancer.</gtr:abstractText><gtr:technicalSummary>Kaposi sarcoma is the most common cancer in HIV-1 infected individuals. KS is a tumour at the interface of infection, immunity and cancer. Kaposi sarcoma herpesvirus (KSHV or HHV-8) is the infectious cause of this neoplasm, and is also associated with certain lymphoproliferations. KS and other KSHV-related tumours also develop during iatrogenic immunosuppression after organ transplantation, inferring that anti-KSHV immunity is central to control tumour formation. We have previously identified and characterised cytotoxic T-lymphocyte responses against this pathogen. We propose here a detail understanding of anti-KSHV immunity. We shall identify and characterise the nature of CD4+ and CD8+ memory T-cell responses both in HIV-1 infected patients and in immunocompetent individuals. We will study the role of natural killer (NK) and dendritic cells (DC) during KSHV infection and whether KSHV interferes with the function of these cells. Simultaneously, we will identify all cell types infected by KSHV in vivo, and identify the viral genes expressed in these cells during latent infection. We will employ classic immunological techniques, as well as genetic screens and gene expression microarrays, to understand the immunobiology of this pathogen. This should form the basis for the design of novel immunotherapeutics and vaccination approaches to treat and prevent infection and malignancy.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1567156</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant and CRT award</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>97902C35-ACF0-4BAA-856B-8FC7B56BC708</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B25A8179-393D-4DCF-A704-5D97A9A8D760"><gtr:id>B25A8179-393D-4DCF-A704-5D97A9A8D760</gtr:id><gtr:title>Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/628e455600b6d314f783a56f80a6e3e7"><gtr:id>628e455600b6d314f783a56f80a6e3e7</gtr:id><gtr:otherNames>Flanagan JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/517274D4-465D-401A-9411-F0FBA2EF2E84"><gtr:id>517274D4-465D-401A-9411-F0FBA2EF2E84</gtr:id><gtr:title>Lentiviral manipulation of gene expression in human adult and embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Tissue engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d499a3234717eea12ba44635f55d31d9"><gtr:id>d499a3234717eea12ba44635f55d31d9</gtr:id><gtr:otherNames>Clements MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1076-3279</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6A9A223-A382-4B6D-BD01-4588959074D7"><gtr:id>B6A9A223-A382-4B6D-BD01-4588959074D7</gtr:id><gtr:title>Endothelial cells and cancer.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98493910014bc03f9fd3a5e585b682ab"><gtr:id>98493910014bc03f9fd3a5e585b682ab</gtr:id><gtr:otherNames>Nikitenko L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B2D0F2A-CF2D-4EA7-AACF-08D149434BE6"><gtr:id>7B2D0F2A-CF2D-4EA7-AACF-08D149434BE6</gtr:id><gtr:title>Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71c13663cd7f25b4656bcd671aa8c3a7"><gtr:id>71c13663cd7f25b4656bcd671aa8c3a7</gtr:id><gtr:otherNames>Lagos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9825083</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>